A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

This study is testing a combination of two drugs — BL-B01D1 (an antibody-drug conjugate that delivers chemotherapy directly to cancer cells) and a PD-1 immune checkpoint inhibitor — in people with advanced non-small cell lung cancer or nasopharyngeal carcinoma (cancer in the back of the nose/throat) that has not responded to previous treatment. **You may be eligible if...** - You are 18 years old or older - You have advanced non-small cell lung cancer or nasopharyngeal carcinoma confirmed by biopsy - Your cancer has at least one measurable area - You are generally in good health and able to carry out daily activities (ECOG 0 or 1) - Your blood counts, heart, liver, and kidneys are functioning adequately **You may NOT be eligible if...** - You have uncontrolled heart arrhythmia or heart ejection fraction below 50% - You have active autoimmune disease or a history of organ transplant - You have HIV, active Hepatitis B or C, or active tuberculosis - You have received another cancer drug or clinical trial treatment within 4 weeks - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.